Form 8-K - Current report:
SEC Accession No. 0001641172-25-000525
Filing Date
2025-03-25
Accepted
2025-03-25 09:00:10
Documents
17
Period of Report
2025-03-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 50788
2 ex10-1.htm EX-10.1 130501
3 ex99-1.htm EX-99.1 35102
4 ex10-1_001.jpg GRAPHIC 196431
5 ex10-1_002.jpg GRAPHIC 54856
  Complete submission text file 0001641172-25-000525.txt   779181

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE mgrx-20250320.xsd EX-101.SCH 3033
7 XBRL LABEL FILE mgrx-20250320_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE mgrx-20250320_pre.xml EX-101.PRE 22371
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3892
Mailing Address 15110 DALLAS PKWY, SUITE 600 DALLAS TX 75248
Business Address 15110 DALLAS PKWY, SUITE 600 DALLAS TX 75248 (833) 626-4679
MANGOCEUTICALS, INC. (Filer) CIK: 0001938046 (see all company filings)

EIN.: 873841292 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41615 | Film No.: 25766057
SIC: 8090 Services-Misc Health & Allied Services, NEC
(CF Office: 03 Life Sciences)